🟢 Strong Evidence
A head-to-head human clinical trial published in Nature Metabolism (2025) reveals that different NAD⁺ precursors follow distinct metabolic pathways after ingestion, with profound implications for how the body processes these compounds and their effects on cellular energy and gut health. The study compared three commonly supplemented precursors—nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN)—in direct human subjects over both acute and chronic dosing periods, showing that bioavailability and systemic effects depend critically on where in the gastrointestinal tract metabolism occurs.
Key takeaways
- Nicotinamide produces rapid but short-lived NAD⁺ increases via direct salvage pathway metabolism in the upper gut
- Nicotinamide riboside and NMN are poorly absorbed intact; they reach the colon where gut microbiota convert them to nicotinic acid, driving sustained NAD⁺ elevation via the Preiss–Handler pathway
- NR and NMN stimulate microbial metabolism, increasing short-chain fatty acid production and altering gut microbiome activity—a dual effect on systemic NAD⁺ and intestinal health
Study at a Glance
| Source | Nature Metabolism |
| Study type | Randomized human clinical trial with acute and chronic dosing phases |
| Population | Healthy human volunteers (n not specified in summary) |
| Comparison | Nicotinamide (NAM) vs. Nicotinamide Riboside (NR) vs. Nicotinamide Mononucleotide (NMN) |
| Outcome measures | NAD⁺ bioavailability, blood NAD⁺ levels, gut microbiome metabolites, short-chain fatty acid production |
NAD⁺ Precursor Metabolism: Absorption Location and Duration of Effect
Comparative bioavailability profiles from human clinical trial; NAM shows rapid peak and decline, while NR and NMN show sustained elevation via microbiota conversion
Source: Nature Metabolism, 2025 (doi: 10.1038/s42255-025-01421-8) | Georgian Medical Journal News
Nicotinamide Takes the Direct Route
Nicotinamide (NAM), the simplest NAD⁺ precursor, is rapidly absorbed in the upper gastrointestinal tract and enters the salvage pathway—a direct metabolic route that efficiently converts NAM back to NAD⁺. According to the Nature Metabolism study, this results in a swift spike in blood NAD⁺ levels, but the elevation is transient and short-lived. This rapid kinetics reflects the fact that the body’s salvage pathway is highly efficient at recycling NAM—but also means the NAD⁺-boosting effect does not persist long after ingestion.
The practical implication is that NAM-based supplementation may provide acute metabolic effects but offers no sustained systemic NAD⁺ elevation over time. This mechanism also explains why frequent dosing schedules are often recommended for nicotinamide products in clinical practice.
NR and NMN Depend on Gut Microbiota for Bioavailability
In striking contrast, the human trial data show that nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are poorly absorbed intact in the small intestine. Instead, these larger molecules transit to the colon, where the gut microbiota metabolizes them into nicotinic acid (NA)—a process that converts a substrate the microbiome can utilize into a metabolite that re-enters human circulation. This indirect route fundamentally alters the kinetics and magnitude of NAD⁺ elevation compared with direct nicotinamide absorption.
Once converted to nicotinic acid by colonic bacteria, the compound enters the Preiss–Handler pathway—a well-characterized route of NAD⁺ synthesis—leading to a sustained increase in whole-blood NAD⁺ levels. This dependency on microbial conversion explains both the delayed onset (compared with NAM) and the prolonged duration of systemic NAD⁺ elevation. It also introduces an important variable: individual differences in gut microbiota composition and activity could substantially affect the bioavailability of NR and NMN between people.
Dual Effects: Systemic NAD⁺ and Gut Microbiome Health
Beyond raising NAD⁺, the Nature Metabolism findings reveal that NR and NMN stimulate microbial metabolism, increasing short-chain fatty acid (SCFA) production—particularly butyrate and propionate. These metabolites are themselves signaling molecules with anti-inflammatory and metabolic effects. The study demonstrates that consuming NR or NMN not only raises systemic NAD⁺ but also alters the functional output of the gut ecosystem itself, potentially conferring dual benefits on both cellular energy metabolism and intestinal health.
Nicotinamide, by contrast, does not engage the microbiota in this way because it is absorbed and metabolized before reaching the colon in significant amounts. This suggests that the choice of NAD⁺ precursor may have implications not only for NAD⁺ kinetics but also for the overall metabolic health of the gut microbiome—a finding that complicates simple “one-size-fits-all” supplementation strategies.
Different NAD⁺ precursors follow fundamentally different metabolic routes: nicotinamide is rapidly absorbed and produces transient NAD⁺ elevation via the salvage pathway, while nicotinamide riboside and nicotinamide mononucleotide are poorly absorbed intact and depend on gut microbiota to convert them to nicotinic acid, resulting in sustained systemic NAD⁺ elevation via the Preiss–Handler pathway.
— Nature Metabolism (2025, doi: 10.1038/s42255-025-01421-8)
What this means
Frequently asked questions
Why does nicotinamide work faster than NR or NMN?
Nicotinamide is a smaller, water-soluble molecule that is efficiently absorbed by active transporters in the small intestine, allowing it to enter the salvage pathway and raise NAD⁺ within minutes to hours. In contrast, NR and NMN are larger nucleosides that are poorly absorbed intact and must transit to the colon for microbial conversion before entering circulation—a process that takes longer but produces sustained elevation.
Does everyone’s gut microbiota convert NR and NMN equally well?
No. The Nature Metabolism study demonstrates the mechanism but does not fully characterize individual variability. Differences in bacterial species composition, metabolic capacity, and colonic pH could all affect the efficiency of conversion. Patients with dysbiosis, antibiotic use, or low microbial diversity may have reduced bioavailability of NR and NMN.
Can I combine NAD⁺ precursors for better results?
The trial did not evaluate combination dosing, so evidence is lacking. However, pharmacokinetic logic suggests that combining precursors might produce both rapid (from NAM) and sustained (from NR/NMN) NAD⁺ elevation. Individual tolerance, microbiota effects, and safety of chronic combined dosing remain unstudied in humans and should not be assumed without clinical evidence.
As research on NAD⁺ metabolism advances, these mechanistic findings underscore a broader lesson: the route of metabolism, not just the dose, determines a supplement’s systemic effect. Future studies should focus on identifying which patient populations—defined by microbiota composition, age, metabolic health, or disease state—derive the greatest benefit from each precursor class, and whether microbiota-targeted interventions (e.g., prebiotics or targeted probiotics) can optimize NR and NMN bioavailability.
Source: Nature Metabolism, 2025 (doi: 10.1038/s42255-025-01421-8)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
